» Articles » PMID: 24161263

Glycan Structure Determinants for Cation-independent Mannose 6-phosphate Receptor Binding and Cellular Uptake of a Recombinant Protein

Overview
Journal Bioconjug Chem
Specialty Biochemistry
Date 2013 Oct 29
PMID 24161263
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The cation-independent mannose 6-phosphate receptor (CI-MPR) plays a critical role in intracellular transport of lysosomal enzymes as well as the uptake of recombinant proteins. To define the minimal glycan structure determinants necessary for receptor binding and cellular uptake, we synthesized a series of glycans containing mono-, di-, tri-, tetra-, and hexamannoses terminated with either one or two phosphates for conjugating to a model protein, recombinant human acid α-glucosidase. A high affinity interaction with the CI-MPR can be achieved for the enzyme conjugated to a dimannose glycan with a single phosphate. However, tightest binding to a CI-MPR affinity column was observed with a hexamannose structure containing two phosphates. Moreover, maximal cellular uptake and a 5-fold improvement in in vivo potency were achieved when the bisphosphorylated hexamannose glycan is conjugated to the protein by a β linker. Nevertheless, even a monophosphorylated dimannose glycan conjugate showed stronger binding to the receptor affinity column, higher cellular uptake, and significantly greater in vivo efficacy compared to the unconjugated protein which contains a low level of high affinity glycan structure. These results demonstrate that the phosphorylated dimannose moiety appears to be the minimal structure determinant for enhanced CI-MPR binding and that the orientation of the glycan is critical for maximum receptor interaction. In summary, we have improved the understanding of the mechanism of CI-MPR binding and developed a simple alternative for CI-MPR targeting.

Citing Articles

Efficacy and safety of avalglucosidase alfa in Japanese patients with late-onset and infantile-onset Pompe diseases: A case series from clinical trials.

Mori-Yoshimura M, Ohki H, Mashimo H, Inoue K, Kumada S, Kiyono T Mol Genet Metab Rep. 2025; 42():101163.

PMID: 39835171 PMC: 11743810. DOI: 10.1016/j.ymgmr.2024.101163.


Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan.

Mukai K, Cost R, Zhang X, Condiff E, Cotton J, Liu X MAbs. 2024; 16(1):2415333.

PMID: 39434219 PMC: 11497922. DOI: 10.1080/19420862.2024.2415333.


Neurological glycogen storage diseases and emerging therapeutics.

Colpaert M, Singh P, Donohue K, Pires N, Fuller D, Corti M Neurotherapeutics. 2024; 21(5):e00446.

PMID: 39277505 PMC: 11581880. DOI: 10.1016/j.neurot.2024.e00446.


Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice.

Tsukimura T, Shiga T, Togawa T, Sakuraba H Mol Genet Metab Rep. 2024; 40:101118.

PMID: 39257531 PMC: 11384131. DOI: 10.1016/j.ymgmr.2024.101118.


Real-world evidence study finds no new-onset diabetes or drug-related hyperglycemia in Pompe disease patients treated with avalglucosidase alfa.

Dumitriu A, Lucas A, Colzani R Mol Genet Metab Rep. 2024; 38:101064.

PMID: 38469102 PMC: 10926186. DOI: 10.1016/j.ymgmr.2024.101064.